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Background: Low adiponectin levels in polycystic ovarian syndrome (PCOS) have been largely attributed to obesity
which is common among these patients. In addition, evidence also suggests that low adiponectin in PCOS may be
related to insulin resistance (IR) in these women. However, studies on the role of adiponectin in younger and lean
patients are limited. Therefore, the aim of the present study was to examine the association of adiponectin levels in
young and lean women with PCOS.
Methods: A case–control study was conducted at the Dow University of Health Sciences, Karachi, Pakistan. Cases
were 75 patients of PCOS with Body Mass Index (BMI) <23 aged 16–35 years and 75 healthy age and BMI matched
controls were selected from family and friends of the cases. Demographic details, family history and past medical
history were obtained through interview by a physician. Anthropometric measurements included weight and
height of the participants. Fasting glucose, total cholesterol, high-density lipoprotein (HDL), insulin, adiponectin, and
androgen levels were determined. IR was calculated using homeostasis model assessment for insulin resistance
(HOMA-IR). Logistic regression models were used to assess the association between adiponectin and PCOS after
adjusting for co-variates.
Results: On multivariable analysis, PCOS cases were 3.2 times more likely to have low adiponectin level (OR = 3.2,
95% CI 1.49-6.90, p-value 0.003) compared to the controls after adjustment for age, BMI, family history, marital status,
total cholesterol, HDL level and IR. Females with a family history of PCOS were significantly more likely to have
lower adiponectin (OR = 3.32, 95% CI 1.27-8.67, p-value 0.014) compared to those who did not have a family history
of PCOS. The associations of IR and family history with low adiponectin level also remained statistically significant
after adjustments for covariates.
Conclusion: Serum adiponectin levels are independently associated with PCOS and are only partly explained by IR.
Adiponectin level may serve as a potential independent biomarker for diagnosis of PCOS in young and lean
women with fewer symptoms, or women with a family history of PCOS.Introduction
The polycystic ovarian syndrome (PCOS) is the most
common endocrine disorder affecting reproductive age
women worldwide [1]. Clinical features of PCOS namely
hirsutism, acne, and alopecia originate from high circulat-
ing levels of androgens, menstrual irregularities from an-
ovulatory cycles [2], and obesity is thought to originate
from both the underlying IR [1] and high androgen levels
in these patients [3]. The alarming tribulations associated* Correspondence: Kashif.shafique@glasgow.ac.uk
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stated.with the syndrome are past the reproductive axis and
these women are at a greater risk of developing the meta-
bolic syndrome at an early age because of IR and obesity
[4-6] observed in 30-60% of PCOS patients [7].
In recent years, role of adipose tissue hormones, particu-
larly adiponectin has been implicated in the pathogenesis
of PCOS [8,9]. Adiponectin has antiatherogenic, anti-
diabetic, anti-inflammatory and insulin sensitizing effects,
and is negatively related to the degree of adiposity in
healthy individuals [10]. Despite being an adipokine, low
levels of adiponectin have been found more closely related
to the degree of IR than adiposity itself [11]. Studies have
also shown that both insulin action and circulating levels
of adiponectin are lower in women with PCOS [12].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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PCOS between different countries. Furthermore, its typical
features like a combination of obesity, hirsutism, acne, alo-
pecia, and irregular menstruation [13] are absent in many
women whereas patients manifest with PCOS at a younger
age, and without any significant history of its symptoms.
Also, obesity and symptoms of hyperandrogenism are also
lower in those patients who are lean and presenting a
younger age [13].
Although low adiponectin levels have been associated
with PCOS which is mainly attributed to obesity among
these patients, studies have also suggested that low adipo-
nectin in PCOS may be related to IR in these women.
However, the role of adiponectin in younger and lean pa-
tients has been examined only in few studies. In these
women, it is not certain that to what extent, the IR deter-
mines the levels of adiponectin. If adiponectin levels in
younger and lean women provide similar association with
PCOS as in obese patients, the level of adiponectin may
be a useful proxy measure of an ongoing ovarian disease
in women with atypical presentation of PCOS. Therefore,
we examined the association of adiponectin levels with
PCOS in younger and lean women.Methods
Selection of cases
We recruited 75 newly diagnosed PCOS patients aged be-
tween 16–35 years with desirable BMI, from the out-
patient departments of Gynecology units of two public
sector hospitals Civil hospital Karachiand Lady Dufferin
hospital, Karachi, Pakistan. Desirable BMI was defined as
BMI < 23 according to the Asian reference values for BMI
[14]. PCOS was diagnosed using the Rotterdam Criteria
[15] which states that PCOS is diagnosed if patient have
any two of the following three features, 1) oligo/amenor-
rhea and/or anovulation, 2) hyperandrogenism and/or
hyperandrogenemia, and 3) polycystic ovaries on ultra-
sound after exclusion of other etiologies. Oligomenorrhea
was defined as infrequent menstruation or less than 9
menstrual periods per year. Amenorrhea was defined as
absence or abnormal cessation of menses for three months
or more [15]. For diagnostic purposes, since we recruited
already diagnosed patients of PCOS, presence of either
clinical hyperandrogenism or biochemical hyperandrogen-
emia was considered acceptable, whichever used by the
diagnosing gynecologist. Hyperandrogenism was defined
as a score of 7 or more on the Ferriman Gallaway index,
or apparent severe hirsutism, acne and alopecia [2].
We did not include pregnant PCOS patients. In
addition, patients with type 2 diabetes mellitus, chronic
liver disease, thyroid dysfunction, and using medications
such as steroids, contraceptives, hypoglycemic/antidiabetic
drugs were not included in the study.Selection of controls
Controls were 75 age-matched healthy females with
regular menstrual cycle from family and friends of the
cases. Controls also had BMI within desirable range.
Females taking medication, including steroids and con-
traceptives were not included.
Demographic information, detailed menstrual and repro-
ductive history, family history of menstrual or reproductive
problems, past medical history, and anthropometric profile
were recorded. Fasting blood samples were drawn from all
participants for assessment of blood glucose, lipid profile,
adiponectin, insulin and androgen levels. Fasting serum
adiponectin was estimated using the Bio-Rad PR 3100
which uses Enzyme Linked ImmunoSorbent Assay
(ELISA) technique of quantitative hormone estimation.
Adiponectin was categorized using the median value of
the sample, 13.0 μU/ml.
Written informed consent was obtained from all study
participants. The study was approved by the Ethics Com-
mittee/Institutional Review Board (IRB), Dow University
of Health Sciences.
Covariates
Age, marital status, family history of PCOS, BMI, IR, total
blood cholesterol level and HDL were used as covariates.
Age was categorized into 5-year age groups. For marital
status, women were grouped into married and unmarried.
Family history was inquired during the interview. Partici-
pants were asked questions about the presence/history of
the following complaints in their first degree (mother and/
or sisters), and/or second degree (aunts and/or cousins)
relatives:
1. History of PCOS
2. History of any menstrual problems
3. Problems in conception
4. Excess facial hair, baldness, and/or acne resistant to
treatment
From the last three questions, presence of any two,
was also considered as a positive history of PCOS, and
finally participants were categorized as having a negative
or a positive family history of PCOS.
BMI was calculated using the standard formula. IR
was calculated using HOMA-IR [16]. HOMA-IR calcu-
lates the IR by dividing the product of fasting blood glu-
cose level (mg/dl) and serum insulin level (μU/ml) by a
constant, i.e. 405. A HOMA-IR value of 2.5 or above
were considered as insulin resistant [16]. Fasting blood
glucose was estimated using the automatic biochemical
analyzer (Hitachi 902) which uses the photometric tech-
nique of glucose estimation. Fasting serum insulin was
estimated, using IMMULITE 1000 analyzer which is a
solid-phase, two site chemiluminescentimmunometric
Table 1 Socio-demographic and biochemical
characteristics of PCOS cases and controls
Cases Controls P-value
Characteristics n (%)* n (%)*
Total participants 75 (50.0) 75 (50.0)
Age, mean(SD) 25.7 (6.0) 25.4 (6.3) 0.76
Age, categorical
16-20 17 (22.7) 19 (25.3) 0.98
21-25 22 (29.3) 22 (29.3)
26-30 12 (16.0) 11 (14.7)
31-35 24 (32.0) 23 (30.7)
Marital status
Unmarried 38 (50.7) 32 (42.7) 0.33
Married 37 (49.3) 43 (57.3)
Family history of PCOS
No 63 (84.0) 54 (72.0) 0.08
Yes 12 (16.0) 21 (28.0)
Body mass index, mean (SD) 19.3 (2.6) 18.3 (2.4) 0.02
Total cholesterol
<6.2 68 (90.7) 69 (92.0) 0.72
≥6.2 7 (9.3) 6 (8.0)
High density lipoprotein
<1.29 35 (46.7) 43 (57.3) 0.19
≥1.29 40 (53.3) 32 (42.7)
Insulin resistance 3.1 (2.1) 2.9 (2.7) 0.73
Adiponectin level, mean (SD) 12.4 (2.7) 18.2 (7.8) <0.01
Adiponectin level, categorical
≤13.0 27 (36.0) 45 (60.0) <0.01
>13.0 48 (64.0) 30 (40.0)
*n and percentages are mentioned until stated otherwise.
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were the parameters of interest) was done by enzymatic
calorimetric test. We measured free serum testosterone
in fasting state; hyperandrogenemia was defined as free
serum testosterone levels higher than 100 ng/ml [17].
Statistical analysis
Data were analyzed using the STATA Software Version 12
(StataCorp, College Station, TX, USA). Results are presented
as means and standard deviations. Threshold for statistical
significance was set at p < 0.05. Socio-demographic and
other biochemical measures were compared between cases
and control using the independent sample t-test and chi-
squared test for continuous and categorical variables,
respectively. To analyze the association between study var-
iables, adiponectin was used as the dependent variable
and age, marital status, family history of PCOS, BMI, total
cholesterol, HDL and IR were used as independent vari-
ables in logistic regression models. To assess the associ-
ation between adiponectin with PCOS, both univariable
and multivariable models were used. Multivariable regres-
sion model included age, marital status, family history of
PCOS, BMI, total cholesterol, HDL, and IR as co-variates.
Results
A total of 150 individuals participated in this study, of
which 75 were diagnosed PCOS cases and 75 controls. The
mean age of sample was 25.6 (SD 6.12), with no statistically
significant difference between cases and controls (p-value
0.76). The majority of participants were married (n = 80,
53.3%), with no significant difference in distribution of mar-
ried individuals between cases and controls (p-value 0.33).
Furthermore, there was no significant difference in total
cholesterol (p-value 0.72), HDL (p-value 0.19) and family
history of PCOS among cases and controls (p-value 0.08).
However, there were significant differences in BMI and
adiponectin level between cases and controls. PCOS Cases
had significantly higher BMI (mean difference 0.97, p-
value .02) and lower adiponectin level (mean difference
5.73, p-value <0.001). The demographic and other charac-
teristics of study sample are described in Table 1.
Univariable analysis to assess the association between
PCOS and adiponectin level (adiponectin ≤13.0), revealed
that cases were 2.7 times more likely (OR = 2.67, 95% CI
1.38-5.16, p-value 0.004) to have lower adiponectin com-
pared to controls. Females with a family history of PCOS
were significantly more likely to have to lower adiponectin
(OR = 3.11, 95% CI 1.33-7.26, p-value 0.009) compared to
those who did not have a family history of PCOS (Table 2).
IR also showed a statistically significant negative associ-
ation with low adiponectin (p-value 0.001). Other factors
including age, BMI, marital status, total cholesterol level
and HDL did not show statistically significant association
with adiponectin (Table 2).On multivariable analysis, the overall findings of univari-
able analysis remained consistent. PCOS cases were 3.2
times more likely to have low adiponectin level (OR = 3.2,
95% CI 1.49-6.90, p-value 0.003) compared to controls
after adjustment for age, BMI, family history, marital
status, total cholesterol level, HDL and IR. The associa-
tions of IR and family history with low adiponectin level
also remained statistically significant after adjustments for
covariates (Table 2).
A stratified analysis was also carried out based on age cat-
egories (≤25 years and >25 years) to assess the association
of low adiponectin with PCOS. PCOS cases of age ≤25 years
were 2.5 times more likely to have low adiponectin while
cases of age >25 years were 2.9 times more likely to have
low adiponectin, compared to their respective control
groups (Figure 1). These associations changed slightly and
remained statistically significant after adjustment for age,
BMI, family history, marital status, total cholesterol level,
HDL level and IR (Figure 1).
Table 2 The relationship of PCOS and other characteristics of low adiponectin level
Univariate analysis
P-value
Multivariate analysis
P-value
Characteristics Odds ratio (95% CI) Odds ratio (95% CI)
PCOS status
Controls 1 1
Cases 2.67 (1.38-5.16) 0.004 3.20 (1.49-6.90) 0.003
Age, categorical
16-20 1 1
21-25 0.54 (0.22-1.32) 0.179 0.53 (0.19-1.43) 0.207
26-30 1.34 (0.45-3.96) 0.597 0.92 (0.17-4.89) 0.924
31-35 0.68 0.29-1.64) 0.396 0.57 (0.12-2.71) 0.479
Marital status
Unmarried 1 1 0.928
Married 0.94 (0.49-1.78) 0.844 1.06 (0.27-4.13)
Family history of PCOS
No 1 1 0.014
Yes 3.11 (1.33-7.26) 0.009 3.32 (1.27-8.67)
Body mass index, mean (SD) 1.09 (0.96-1.24) 0.163 0.97 (0.84-1.13) 0.721
Total cholesterol
<6.2 1 1 0.268
≥6.2 1.53 (0.47-4.92) 0.474 2.06 (0.57-7.40)
High density lipoprotein
<1.29 1 1 0.482
≥1.29 1.63 (0.86-3.12) 0.137 1.30 (0.63-2.69)
Insulin resistance 1.29 (1.11-1.52) 0.001 1.23 (1.03-1.47) 0.023
Multivariate model include all covariates presented in this table.
Figure 1 Age-specific relationship between PCOS and adiponectin level. Adjusted odds ratio are estimated after accounting for BMI, family
history of PCOS, marital status, total cholesterol level, high density lipoprotein level and insulin resistance.
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Our findings suggest that PCOS women with a desir-
able BMI are significantly more likely to have low
serum adiponectin levels. The association of PCOS
with low adiponectin level remained consistent and
statistically significant after adjustment for age, BMI,
family history of PCOS, marital status, total cholesterol
level, HDL and IR. This relationship between PCOS
and low adiponectin also changed a little across differ-
ent age groups. Furthermore, family histories of PCOS
and IR were also significantly associated with lower
adiponectin levels. We found low levels of adiponectin
in lean young women with PCOS. Several studies have
demonstrated reduced levels of serum adiponectin in
women with PCOS [12,18-23]. Also, few of them have
shown an association of low adiponectin levels in
PCOS women irrespective of the weight and/or BMI of
patients [12,18,20-22].
A systematic review and meta-analysis by Toulis
et al., on a sub-analysis by using studies only with
PCOS cases and controls matched on BMI, revealed
that PCOS women had lower levels of adiponectin
after controlling for the potential effects of obesity by
BMI matching. This suggests that serum adiponectin
levels are not independently determined by the degree
of adiposity in women but underlying disease may also
have some role. A possible explanation for this finding
is that lower adiponectin levels in PCOS women might
be a result of increasing IR in these patients [1] as sup-
ported by our study. As adiponectin is known to pos-
sess insulin-sensitizing, anti-diabetic properties and
reduced circulating levels are also observed in type 2
diabetes mellitus [24], IR might possibly be a link be-
tween lower adiponectin level and development of
polycystic ovarian syndrome; however, whether low
adiponectin is a cause or a consequence of IR in PCOS
remains debated. In addition, it has been observed in
randomized controlled trials that treatment of PCOS
patients with anti-diabetic medication as metformin
[25,26], rosiglitazone [27], and pioglitazone [28], in
addition to reductions in secretion of insulin and im-
provement in its action on glucose metabolism, also in-
creases the adiponectin levels in circulation. However,
in multivariable analysis, we observed lower adiponec-
tin levels in women with PCOS, after adjusting for all
possible confounders stated, including IR. Stratified
analysis (data not shown) based on IR also showed a
lower adiponectin level in PCOS women, suggesting
that adiponectin levels in these women are regulated
by certain unexplained factors other than IR. It could
be possible that genetically predisposed women to
PCOS might exhibit a lower secretion of adiponectin
which may lead to other features/symptoms of PCOS
with time.We have also found an association of family history of
PCOS and IR with lower adiponectin levels in PCOS
women. Increasing evidence suggests that genetic factors
play an important role in the pathogenesis of PCOS. Inter-
estingly, prevalence of PCOS in South East Asians settled
in United Kingdom was 52%, which is an 18% higher rate
than the native population, suggestive of some genetic pre-
disposition of PCOS among certain races [29]. In addition
to familial clustering of PCOS in first degree relatives [30],
it has been shown that the pre-pubertal daughters with
normal BMI, of women with PCOS, manifest with dis-
turbed metabolic profile including hypoadiponectenemia
and hyperinsulinemia compared to daughters of healthy
women [31]. In our study, controls were recruited from
the family and friends of the cases. Cases and controls did
not differ significantly regarding the history of PCOS. This
might be argued that as history of PCOS is strongly related
to the incidence of PCOS, however, it is not necessary that
persons having PCOS always have a history of PCOS. This
points towards the hypothesis that, although family history
is an important risk factor, environmental triggers are also
playing a role, e.g. diet, and exercise. In addition, PCOS is a
syndrome and a polygenic causality cannot be ruled out.
Dysfunctional changes in the metabolism of carbohydrates,
insulin action, and steroid hormones have also been impli-
cated. Therefore, a similar family history of PCOS can be
explained as being one of the many contributory factors
that cause PCOS, and a similarity of family history in cases
and controls is not contradictory.
We found significantly lower levels of adiponectin in
PCOS patients <25 years of age. It is possible that the youn-
ger age-group is the group with the involvement of a stron-
ger genetic component in PCOS pathogenesis, which lead
to an early manifestation of disease. This might indicate a
more severe disease phenotype, which may worsen over-
time, and become more resistant to treatment. Longitudinal
studies can provide further insights, to better understand
the course of disease in such patients. As we included lean
women with PCOS, which is also a common presentation
in clinics in Pakistan, our data suggest that lower adiponec-
tin levels in women with PCOS are not only caused by the
IR and obesity in these women. On the contrary, it might
be interplay of family history of PCOS and IR, or these
women have inherent low levels of adiponectin regardless
of their BMI and degree of IR, which leads to development
of the full-blown PCOS. Also, a positive family history of
PCOS may evoke a disturbance in the insulin secretion in
genetically predisposed individuals, giving rise to lower adi-
ponectin levels and polycystic ovaries. Adiponectin thus
may serve as a useful marker in detecting cases of PCOS
with atypical presentation or in individuals with a family
history of PCOS. Longitudinal studies are therefore war-
ranted to understand the initiating point in development of
PCOS in females having a family history of PCOS and IR.
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To our knowledge, this is the first study to investigate
serum adiponectin levels in PCOS women in Pakistani
population. However certain methodological considerations
are worth-mentioning. Sample size was limited and the ef-
fect estimates may not be very precise, however, we found a
statistically significant relationship between PCOS and adi-
ponectin which remained significant even with this smaller
sample. In addition, we calculated IR using HOMA-IR and
not by the euglycemic/hyperglycemic clamp which is the
gold standard to measure IR. However, HOMA-IR is a
worldwide accepted surrogate marker for the calculation of
IR. This may have potentially misclassified some individ-
uals, however such misclassifications are likely to be non-
differential and should lead to a null results. But in our
study, we observed a statistically significant association both
for IR and adiponectin with PCOS, which is unlikely due to
a misclassification bias.
Conclusion
In conclusion, serum adiponectin levels in lean women
with PCOS are only partly explained by IR. Adiponectin
levels may serve as a potential independent biomarker
for diagnosis of PCOS in lean women with fewer symp-
toms, or women with a family history of PCOS. Further
research using prospective design may provide evidence
on role of adiponectin in early diagnosis or detection of
PCOS among young lean women.
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